Your browser doesn't support javascript.
loading
STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma.
Xiao, Shuxin; Fan, Chuanbo; Ma, Jinlong; Xue, Hongwei; Xu, Liqin.
Afiliação
  • Xiao S; Department of Lymphoma and Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Fan C; Department of Hematology, Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), Qingdao, China.
  • Ma J; Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Xue H; Department of Lymphoma and Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Xu L; Department of Hematology and Oncology, Qingdao West Coast New Distinct People's Hospital, Qingdao, China.
Acta Haematol ; 145(4): 371-383, 2022.
Article em En | MEDLINE | ID: mdl-34915482
ABSTRACT
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) is yet to be established. We studied here whether STAT3 contributes to C-C motif chemokine ligand (CCL4) transcription elevation in DLBCL. Our established protein-protein interactions network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/ß-catenin pathway. The prognostic analysis exhibited that the overall survival of patients with high STAT3 and CCL4 were poorer than those with low STAT3 and CCL4 expression. In addition, silencing of STAT3 reverted the malignant phenotype in DLBCL cells. CCL4 overexpression partly weakened the si-STAT3-mediated antitumor effects on DLBCL cells. Tumor xenograft models showed that si-STAT3 inhibited tumor growth in vivo and decreased proliferative and mitogenic activities in tumor tissues, which was consistent with the in vitro data. Hence, this study provides new evidence that STAT3 and CCL4 may be new prognostic biomarkers and therapeutic targets for treating DLBCL.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Fator de Transcrição STAT3 / Quimiocina CCL4 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Fator de Transcrição STAT3 / Quimiocina CCL4 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article